Title | Large spot size-transpupillary laser diode (LSTLD) with or without adjuvant ICG for retinal hemangiomas. |
Purpose | To evaluate the efficacy, ocular and visual outcomes, and treatment complications following a LSTLD (with indirect ophthalmoscopy) with or without ICG as therapeutic approach of vision-threatening retinal hemangiomas (RCH = retinal capillary hemangiomas associated with Von Hippel-Lindau disease or VPT = vasoproliferative tumors). |
Methods | This non comparative observational cases series included 32 retinal hemangiomas (23 RCH and 9 VPT) in 19 eyes (17 patients), all treated by TDL (810 nm) with large spot size-indirect ophthalmoscopy (1.2 mm). 5 tumors (16%) were treated by TDL alone and 27 (84%) by ICG-enhanced TDL. |
Results | After a mean follow-up of 55 months (range: 2 - 234), 15 hemangiomas (47%) presented with a flat scar and 15 (47%) showed regressed fibrotic appearance. Visual acuity improved in 5 eyes (26%), decreased in 3 eyes (16%) and was stable in 11 eyes (58%). Two eyes (11%) developed ablatio fugax and four eyes (21%) epiretinal macular membrane. No other complication was recorded. 7 hemangiomas required a second treatment. |
Conclusion | Large spot size-TLD (1.2mm) with indirect ophthalmoscopy appeared to be a safe therapeutic option for vision-threatening exudative retinal hemangiomas. The only complications were epiretinal macular membrane and ablatio fugax. The potential benefit of ICG injection on tumor and/or exudation regression could not be statistically evaluated due to the small number of treated hemangiomas. |
Conflict of interest | No |
Last name | BARTOSZEK |
Initials | P |
Department | Ocular Oncology Unit, Institut Roi Albert II - Cliniques Universitaires Saint-Luc |
City | Brussels |
Last name | DE POTTER |
Initials | P |
Department | Ocular Oncology Unit, Institut Roi Albert II - Cliniques Universitaires Saint-Luc |
City | Brussels |